Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Clemons

Showing results (21-30 of 267) with videos related to

Pageof 27
Sort By:
The Lancet. Oncology|October 10, 2002
Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategiesAndrew Clamp, Sarah Danson, Mark Clemons
NEJM Evidence|February 6, 2024
How Frequently Should Patients with Breast Cancer Have Routine Follow-Up Visits?Ana-Alicia Beltran-Bless, Mark Clemons
The Lancet. Oncology|September 3, 2013
The ZOOM trial: more boon than doom?Brian Hutton, Christina L Addison, Mark Clemons
European Journal of Cancer (Oxford, England : 1990)|June 15, 2016
Rethinking end-points for bone-targeted therapy in advanced cancerSusana Gómez García, Mark Clemons, Eitan Amir
Journal of the American Dental Association (1939)|April 2, 2011
More about osteonecrosisRichard D Finkelman, Mark Clemons, Nathaniel Bouganim
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Systemic treatment of bone metastases from breast cancer: is it all that it's cracked up to be?Mary C Gainford, George Dranitsaris, Mark Clemons
BMJ (Clinical Research Ed.)|April 2, 2005
Recent developments in bisphosphonates for patients with metastatic breast cancerMary C Gainford, George Dranitsaris, Mark Clemons
The Oncologist|May 8, 2015
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?Terry L Ng, Brian Hutton, Mark Clemons
Journal of Oncology Practice|August 11, 2018
De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?Arif A Awan, Alexander Paterson, Mark Clemons
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|December 12, 2012
Holiday reading: The Mayan Doomsday's effect on survival outcomes in clinical trialsPaul Wheatley-Price, Brian Hutton, Mark Clemons
Pageof 27

Showing results (21-30 of 267) with videos related to

Sort By:
Pageof 27
The Lancet. Oncology|October 10, 2002
Hormonal risk factors for breast cancer: identification, chemoprevention, and other intervention strategiesAndrew Clamp, Sarah Danson, Mark Clemons
NEJM Evidence|February 6, 2024
How Frequently Should Patients with Breast Cancer Have Routine Follow-Up Visits?Ana-Alicia Beltran-Bless, Mark Clemons
The Lancet. Oncology|September 3, 2013
The ZOOM trial: more boon than doom?Brian Hutton, Christina L Addison, Mark Clemons
European Journal of Cancer (Oxford, England : 1990)|June 15, 2016
Rethinking end-points for bone-targeted therapy in advanced cancerSusana Gómez García, Mark Clemons, Eitan Amir
Journal of the American Dental Association (1939)|April 2, 2011
More about osteonecrosisRichard D Finkelman, Mark Clemons, Nathaniel Bouganim
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2005
Systemic treatment of bone metastases from breast cancer: is it all that it's cracked up to be?Mary C Gainford, George Dranitsaris, Mark Clemons
BMJ (Clinical Research Ed.)|April 2, 2005
Recent developments in bisphosphonates for patients with metastatic breast cancerMary C Gainford, George Dranitsaris, Mark Clemons
The Oncologist|May 8, 2015
Chemotherapy-Induced Nausea and Vomiting: Time for More Emphasis on Nausea?Terry L Ng, Brian Hutton, Mark Clemons
Journal of Oncology Practice|August 11, 2018
De-Escalation of Bone-Modifying Agents in Patients With Bone Metastases: The Best of Times and the Worst of Times?Arif A Awan, Alexander Paterson, Mark Clemons
CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne|December 12, 2012
Holiday reading: The Mayan Doomsday's effect on survival outcomes in clinical trialsPaul Wheatley-Price, Brian Hutton, Mark Clemons
Pageof 27